|
|
 |
|
| Technology |
|
 |
|
| Treatment of Helicobacter Pylori Associated Disorders |
|
H. pylori (HP) infection affects >60% of the world’s population and was found
to be associated
with numerous gastrointestinal disorders, e.g. peptic ulcer disease, gastric
adenocarcinoma, gastric MALT lymphoma, dyspepsia, and anemia.
Current treatments are based on “Triple Therapy”, which involves 10-14 days
of treatment with a combination of at least 2 antibacterials and an acid-suppressing
agent (usually PPI). Eradication rates, using this regimen, have been dropping over
time. This has been attributed to an increasing H. pylori resistance to the
antibiotics used; Poor patient compliance with the multi daily drugs used in
leads to a dramatic drop in the cure rate.
VECTA is currently exploring to develop VECAM together with Amoxicillin as a short term,
novel anti-HP treatment.
Employing the robust gastric acid inhibition of VECAM as of first treatment
for utilization of essential host-parasite interaction mechanisms, we suggest that
the combination of VECAM with Amoxicillin will suffice for its eradication and shall
lead to excellent compliance.
|
